Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christine BARTLETT
Date of last notice	30/12/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	CN Bartlett and KR Coles Super Fund	
Date of change	18/04/2023	
No. of securities held prior to change	276,130 Direct – 216,130 Indirect – 60,000	
Class	FPO	
Number acquired	7,446	
Number disposed		
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,286.66	
No. of securities held after change	283,576 Direct – 223,576 Indirect – 60,000	

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares purchased under NED's Share Plan

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	
_	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Gerald MANUEL
Date of last notice	30/12/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	18/04/2023
No. of securities held prior to change	382,610 Direct – 382,610
Class	FPO
Number acquired	6,981
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$4,956.51
No. of securities held after change	389,591 Direct – 389,591

⁺ See chapter 19 for defined terms.

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
to which the interest has changed	
Interest acquired	
Interest disposed	
-	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Kathryn SPARGO
Date of last notice	30/12/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Self-managed superannuation fund of Director Spargo Super Pty Ltd (atf Spargo Super Fund)	
Date of change	18/04/2023	
No. of securities held prior to change	448,212 Direct – 208,212 Indirect – 240,000	
Class	FPO	
Number acquired	8,144	
Number disposed		
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,782.24	
No. of securities held after change	456,356 Direct – 216,356 Indirect – 240,000	

⁺ See chapter 19 for defined terms.

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
to which the interest has changed	
Interest acquired	
Interest disposed	
-	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael SAMMELLS
Date of last notice	30/12/2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	18/04/2023
No. of securities held prior to change	125,383 Direct – 125,383
Class	FPO
Number acquired	13,496
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$9,582.16
No. of securities held after change	138,879 Direct – 138,879

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares purchased under NED's Share Plan

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
•	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
Interest acquired	
interest doquired	
Interest disposed	
mtoroot dioposod	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	
"	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neville MITCHELL
Date of last notice	02/02/2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	18/04/2023
No. of securities held prior to change	0 Direct – 0
Class	FPO
Number acquired	4,091
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$2,904.61
No. of securities held after change	4,091 Direct – 4,091

⁺ See chapter 19 for defined terms.

Nature of change	Shares purchased under NED's Share Plan
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
•	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation	
to which the interest has changed	
to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Canaidanatian	
Value/Consideration	
Note: If consideration is non-cash, provide details and an	
estimated valuation	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.